日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in Mycobacterium kansasii lung disease

临床前药代动力学/药效学研究阐明了乙胺丁醇在堪萨斯分枝杆菌肺病中的作用

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01447-25
Gumbo, Tawanda; Boorgula, Gunavanthi D; Srivastava, Shashikant
发表日期：2026
文献求助 收藏

Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease

在脓肿分枝杆菌肺病的空心纤维系统模型中，依拉环素的药代动力学/药效学研究

期刊:Microbiology Spectrum
影响因子:3.8
doi:10.1128/spectrum.03432-25
Singh, Sanjay; Shrivastava, Avneesh; Boorgula, Gunavanthi D; Long, Mary C; Robbins, Brian; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2026
文献求助 收藏

Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease

在脓肿分枝杆菌肺病的空心纤维系统模型中对依佩曲硼罗进行临床前评价

期刊:Journal of Antimicrobial Chemotherapy
影响因子:3.6
doi:10.1093/jac/dkaf405
Singh, Sanjay; Boorgula, Gunavanthi D; Nguyen, Minh-Vu H; Daley, Charles L; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2026
文献求助 收藏

Novel regimens for treatment of Mycobacterium avium lung disease based on advanced in vitro systems and the mathematics of basis functions

基于先进体外系统和基函数数学的新型鸟分枝杆菌肺病治疗方案

期刊:
影响因子:
doi:10.64898/2026.03.30.715241
Srivastava, Shashikant; Singh, Sanjay; Boorgula, Gunavanthi D; McShane, Pamela J; Gumbo, Tawanda
发表日期：2026
文献求助 收藏

Tigecycline pharmacodynamics in the hollow fiber system of Mycobacterium avium-complex lung disease and the utility of MICs and time-kill studies in drug development

替加环素在鸟分枝杆菌复合群肺病空心纤维系统中的药效学，以及最小抑菌浓度（MIC）和时间杀菌曲线研究在药物研发中的应用

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1682477
Deshpande, Devyani; Srivastava, Shashikant; Gumbo, Tawanda
发表日期：2025
文献求助 收藏

Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease

亚胺培南在临床前中空纤维模型中的药代动力学/药效学、虚拟患者的剂量探索以及治疗脓肿分枝杆菌肺病的临床疗效证据

期刊:Journal of Infectious Diseases
影响因子:4.5
doi:10.1093/infdis/jiae601
Singh, Sanjay; Gumbo, Tawanda; Wang, Jann-Yuan; Boorgula, Gunavanthi D; Burke, Andrew; Huang, Hung-Ling; McShane, Pamela J; Amaro-Galvez, Rodolfo; Gross, Jane E; Aryal, Santosh; Heysell, Scott K; Srivastava, Shashikant
发表日期：2025
文献求助 收藏

Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis

在异质性耐药结核病背景下，氟喹诺酮类药物和利福平联合用药

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01084-24
Vogensen, Vanessa B; Singh, Sanjay; Allende, Christopher J; Engelthaler, David M; Boorgula, Gunavanthi D; Thomas, Tania A; Sturkenboom, Marieke G G; Akkerman, Onno W; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2025
文献求助 收藏

Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis

依哌硼罗在结核分枝杆菌中空纤维系统模型中的药代动力学/药效学

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00481-25
Singh, Sanjay; Devine, Megan; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2025
文献求助 收藏

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus

舒巴坦-度洛巴坦可提高头孢菌素和碳青霉烯类抗生素对脓肿分枝杆菌的敏感性，并延长其杀菌时间。

期刊:Microbiology Spectrum
影响因子:3.8
doi:10.1128/spectrum.01492-25
Shrivastava, Avneesh; Boorgula, Gunavanthi D; Singh, Sanjay; Stiles, Danaleigh; McShane, Pamela J; Devine, Megan; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2025
文献求助 收藏

Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease

舒巴坦-度洛巴坦联合头孢曲松治疗脓肿分枝杆菌肺病的剂量和新型治疗方案

期刊:
影响因子:
doi:10.1101/2025.08.05.668504
Singh, Sanjay; Shrivastava, Avneesh; Boorgula, Gunavanthi D; Long, Mary C; Robbins, Brian; McShane, Pamela J; Gumbo, Tawanda; Srivastava, Shashikant
发表日期：2025
文献求助 收藏